Background-Among individuals without hypertension based on clinic blood pressure (BP), it is unclear who should be screened for masked hypertension, defined as having hypertension based on out-of-clinic BP. We hypothesized that individuals with a higher 10-year predicted atherosclerotic cardiovascular disease (ASCVD) risk, calculated using the pooled cohort risk equations, have a higher prevalence of masked hypertension. Methods and Results-We analyzed data from the Jackson Heart Study-a population-based cohort of blacks-to determine the association of predicted ASCVD risk with masked hypertension. The sample included 644 participants, 40 to 79 years of age, with clinic systolic/diastolic BP <140/90 mm Hg, who completed ambulatory BP monitoring, were free of cardiovascular disease, and had data on factors needed to calculate ASCVD risk. Ten-year predicted ASCVD risk was calculated using the pooled cohort risk equations. Any masked hypertension was defined as masked daytime hypertension (mean daytime systolic/diastolic BP ≥135/85 mm Hg), masked nighttime hypertension (mean nighttime systolic/diastolic BP ≥120/70 mm Hg), or masked 24-hour hypertension (mean 24-hour systolic/diastolic BP ≥130/80 mm Hg). The prevalence of any masked hypertension was 54.0%. Compared with participants in the lowest (<5%) predicted ASCVD risk category, multivariable-adjusted prevalence ratios (95% confidence interval) for any masked hypertension were 1.36 (1.03-1.79), 1.62 (1.22-2.16), and 1.91 (1.47-2.48) for those with ASCVD risk of 5% to <7.5%, 7.5% to <10%, and ≥10%, respectively. The C statistic for discriminating between participants with versus without any masked hypertension was 0.681 (95% confidence interval, 0.640-0.723) for ASCVD risk and 0.703 (95% confidence interval, 0.663-0.744) for clinic systolic BP and diastolic BP. Conclusions-Higher ASCVD risk was associated with an increased prevalence of masked hypertension. Although the discrimination of ASCVD risk for masked hypertension was not superior to clinic BP, risk prediction equations may be useful for identifying the subgroup of individuals with both masked hypertension and high predicted ASCVD risk. (Circ Cardiovasc Qual Outcomes. 2017;10:e003421.
B
lood pressure (BP) is traditionally measured in the clinic setting. However, studies have demonstrated that BP measured in the clinic differs substantially when measured outside of the clinic using ambulatory BP monitoring (ABPM). 1, 2 Masked hypertension, defined as not having hypertension on clinic BP measurements but having hypertension based on daytime BP measurements from outside of the clinic setting, is a common phenotype with prevalence estimates ranging from 15% to 30% in population-based studies. 1 When the definition of masked hypertension includes having hypertension based on nighttime BP, the prevalence has been reported to be substantially higher. 3 Masked hypertension has been associated with an increased risk for atherosclerotic cardiovascular disease (ASCVD) events in several prior studies. [1] [2] [3] [4] [5] [6] 
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It is unclear who should undergo ABPM to identify masked hypertension among adults without hypertension based on BP measured in the clinic. In prior studies, the prevalence of masked hypertension has increased with higher clinic systolic BP (SBP) and diastolic BP (DBP). 1, 2 In addition to higher clinic BP, older age, male sex, smoking, diabetes mellitus, and antihypertensive medication use have each been associated with an increased prevalence of masked hypertension.
factors may be a useful tool for choosing who to screen with ABPM for identifying masked hypertension.
In the current study, we evaluated whether higher 10-year predicted ASCVD risk, assessed using the pooled cohort risk equations, 7 is associated with a higher prevalence of masked hypertension. Additionally, we compared 10-year predicted ASCVD risk to clinic BP for discriminating participants with and without masked hypertension. These analyses were conducted in the JHS (Jackson Heart Study)-a large populationbased cohort of blacks. The results of this study may help identify individuals who should undergo ABPM for detecting masked hypertension.
Methods

Study Population
The JHS-a population-based prospective cohort study-was designed to evaluate cardiovascular disease risk among blacks. 8 Briefly, the JHS enrolled 5306 noninstitutionalized blacks, aged ≥20 years, between 2000 and 2004 from the Atherosclerosis Risk in the Community site in Jackson, MS-a representative sample of urban and rural Jackson-Mississippi metropolitan tricounty (Hinds, Madison, and Rankin counties) residents, volunteers, randomly contacted individuals, and secondary family members of participants. 9, 10 The current analysis was restricted to JHS participants who underwent ABPM after the baseline examination (n=1148). Participants who did not meet the international database on ABPM in relation to cardiovascular outcomes 11 criteria for a complete ABPM recording (n=102; described below) or were missing clinic BP or information on antihypertensive medication use (n=30) were excluded from the current analysis. Because masked hypertension can only be present among individuals without hypertension based on clinic-measured BP (ie, clinic SBP <140 mm Hg and clinic DBP <90 mm Hg), participants who had clinic SBP ≥140 mm Hg or clinic DBP ≥90 mm Hg (n=196) were also excluded. Also, because the pooled cohort risk equations were developed and validated among adults 40 to 79 years of age, participants <40 years of age or >79 years of age (n=51) were excluded. 7 Participants were excluded if they had missing data on ASCVD risk factors (n=64), including age, sex, total cholesterol, high-density lipoprotein cholesterol, smoking status, and diabetes mellitus. Finally, because the pooled cohort risk equations were designed to evaluate predicted ASCVD risk among adults without cardiovascular disease, 7 participants with a history of myocardial infarction or stroke (n=61) were excluded from the current study, leaving a final sample size of 644 participants. The institutional review board governing human subjects' research at the participating institutions approved the JHS protocol and all data collection procedures. All participants provided written informed consent. The current analysis was approved by the Institutional Review Board at Columbia University and University of Alabama at Birmingham.
Data Collection
Detailed descriptions of data collection, methodology, specimen collection, and processing have been previously described. 10, 12 Data for this analysis were collected during the baseline in-home interview and study visit and through ABPM.
Baseline Characteristics
Age, sex, and education were obtained by self-report using standardized interviewer-administered questionnaires. Current smoking was defined by affirmative responses to the questions "Have you smoked more than 400 cigarettes in your lifetime?" and "Do you now smoke cigarettes?" Antihypertensive medication use in the 2 weeks before the study visit was self-reported. Height, weight, and clinic BP were measured, and blood samples were collected by trained staff during the study visit. Body mass index was calculated as weight in kilograms divided by height in meters squared. Total and high-density lipoprotein cholesterol were quantified by an oxidase method. 12 Serum glucose was measured using a glucose oxidase method on a Vitros 250 or 950, ortho-clinical diagnostics analyzer. 12 Hemoglobin A1c was measured using a TOSOH high-performance liquid chromatography system. Diabetes mellitus was defined as a fasting (≥8 hours) serum glucose ≥126 mg/dL or hemoglobin A1c ≥6.5% or self-reported use of insulin or oral hypoglycemic medications within 2 weeks before the study visit. Serum creatinine was measured using a multipoint enzymatic spectrophotometric assay on a Vitros 950, ortho-clinical diagnostic analyzer. Estimated glomerular filtration rate was calculated using the chronic kidney disease epidemiology collaboration equation. 13 Reduced estimated glomerular filtration rate was defined as <60 mL/min/1.73 m 2 .
Clinic BP Measurement
A standardized protocol was followed to measure clinic BP. Participants were asked to avoid caffeine, eating, heavy physical activity, smoking, and alcohol intake for 12 hours before their study visit. An appropriately sized cuff, determined from an arm circumference measurement, and a random-zero sphygmomanometer (Hawksley and Sons, Ltd) were used for the BP measurement. 10, 14 Participants sat for at least 5 minutes in an upright position with their back and arms supported, feet flat on the floor, and legs uncrossed before trained staff conducted 2 BP measurements, separated by 1 minute, in the right arm. The JHS Coordinating Center conducted quality control through training and semiannual retraining of staff, 15 monitoring digit preference for each staff member, and by comparing mean BP measurements within and between trained technicians. As previously described, 16 a BP comparability substudy for which BP was assessed simultaneously, using a Y connector, by random-zero sphygmomanometer and an Omron HEM-907XL oscillometric device was conducted among 2115 JHS participants in 2005 to 2008. The random-zero BP measurements were calibrated to the oscillometric device using robust regression. The average of the 2 clinic BP measurements was used for analysis.
WHAT IS KNOWN
• Blood pressure measured in the clinic can differ substantially from blood pressure measured outside of the clinic assessed using ambulatory blood pressure monitoring.
• Masked hypertension, defined as not having hypertension on clinic blood pressure measurements but having hypertension on ambulatory blood pressure monitoring, is a common phenotype and is associated with an increased risk of cardiovascular disease events.
• Current guidelines do not specify whom with nonelevated clinic blood pressure should be screened for masked hypertension with ambulatory blood pressure monitoring.
WHAT THE STUDY ADDS
• Higher predicted atherosclerotic cardiovascular disease risk using the pooled cohort risk equations is associated with an increased prevalence of masked hypertension among blacks.
• Cardiovascular disease risk prediction equations may be useful in determining whom should be screened for masked hypertension using ABPM.
Ambulatory BP Monitoring
After the baseline study visit, participants were fitted with an ABPM device (Spacelabs 90207) on their nondominant arm. Ambulatory BP was recorded every 20 minutes for 24 hours. Data were evaluated for quality and processed with Medifacts International Medicom software (Rockville, MD). International Database on ABPM in relation to Cardiovascular Outcomes criteria were used to define whether the ABPM measurement was complete. 11 Participants were considered to have a complete ABPM if they had ≥10 daytime (10:00 AM to 8:00 PM) and ≥5 nighttime (midnight to 6:00 AM) SBP and DBP measurements.
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Hypertension Categories
Daytime hypertension was defined as a mean ambulatory SBP ≥135 mm Hg or a mean ambulatory DBP ≥85 mm Hg using BP measurements obtained between 10:00 AM and 8:00 PM. 17 Nighttime hypertension was defined by a mean ambulatory SBP ≥120 mm Hg or a mean ambulatory DBP ≥70 mm Hg using BP measurements obtained between midnight and 6:00 AM, and 24-hour hypertension was defined as a mean ambulatory SBP ≥130 mm Hg or a mean ambulatory DBP ≥80 mm Hg using all BP measurements obtained on ABPM. 17 As the current analysis was restricted to participants with clinic SBP <140 mm Hg and clinic DBP <90 mm Hg, those with daytime, nighttime, and 24-hour hypertension were considered to have masked daytime hypertension, masked nighttime hypertension, and masked 24-hour hypertension, respectively. Participants with masked daytime hypertension, masked nighttime hypertension, or masked 24-hour hypertension were categorized as having any masked hypertension. Participants were categorized as either having prehypertension, defined by a mean clinic SBP 120 to 139 mm Hg or a mean clinic DBP 80 to 89 mm Hg, or normal clinic BP, defined by a mean clinic SBP <120 mm Hg and a mean clinic DBP <80 mm Hg. For participants taking antihypertensive medication, on-treatment clinic SBP/DBP of 120 to 139/80 to 89 mm Hg and masked uncontrolled hypertension are corresponding terms for prehypertension and masked hypertension, respectively. 18 For simplicity in the presentation of the results, we use the terms prehypertension and masked hypertension for all participants, regardless of antihypertensive medication use.
Ten-Year Predicted ASCVD Risk
In 2013, the American College of Cardiology and American Heart Association recommended the use of the pooled cohort risk equations for estimating 10-year ASCVD risk. 7 There are 4 race-and sex-specific pooled cohort risk equations, each of which uses age, total cholesterol, high-density lipoprotein cholesterol, clinic SBP, and status of antihypertensive medication use, current smoking, and diabetes mellitus to calculate 10-year predicted ASCVD risk. 19 For the primary analyses, participants were categorized into four 10-year predicted ASCVD risk categories: <5%, 5% to <7.5%, 7.5% to <10%, and ≥10%. 
Statistical Analyses
Participant characteristics were calculated by 10-year predicted ASCVD risk category for the overall analytic sample and for those taking and not taking antihypertensive medication, separately. Herein, we describe the analysis for any masked hypertension. Identical analyses were performed for masked daytime hypertension, masked nighttime hypertension, and masked 24-hour hypertension. The prevalence of any masked hypertension was calculated by category of 10-year predicted ASCVD risk. Using the lowest 10-year predicted ASCVD risk category (<5%) as the referent group, prevalence ratios (95% confidence interval [CI]) for any masked hypertension were calculated for participants with 10-year predicted ASCVD risk of 5% to <7.5%, 7.5% to <10%, and ≥10%. Associations were examined in an unadjusted model and after adjustment for age, sex, body mass index, less than high school education, and reduced estimated glomerular filtration rate.
The P-trend across the categories was calculated by modeling category of 10-year predicted ASCVD risk as a continuous variable using a Cochran-Armitage test for trend. Analyses were repeated for participants taking and not taking antihypertensive medication, separately. Because of a limited sample size being available in some subgroups, participants were grouped into 3 categories of 10-year predicted ASCVD risk (<5%, 5% to <7.5%, and ≥7.5%) for these stratified analyses. The distribution of 10-year predicted ASCVD risk categories was then calculated for participants with and without any masked hypertension, separately.
As previous studies have demonstrated a substantial diagnostic overlap between prehypertension and masked hypertension, 6 ,20,21 the prevalence and prevalence ratios (95% CI) for any masked hypertension associated with 10-year predicted ASCVD risk were calculated for participants with prehypertension and normal clinic BP, separately. Also, adjusted prevalence ratios (95% CI) for any masked hypertension were calculated for each SD higher 10-year predicted ASCVD risk, clinic SBP, and clinic DBP.
The ability of the 10-year predicted ASCVD risk score and clinic SBP and DBP, clinic SBP alone, and clinic DBP alone to discriminate between participants with versus without any masked hypertension was determined by calculating C statistics. Differences in the C statistics were calculated comparing clinic SBP and clinic DBP together, clinic SBP alone, and clinic DBP alone versus 10-year predicted ASCVD risk. Also, differences in C statistics were calculated comparing clinic SBP and DBP versus clinic SBP alone and separately, clinic DBP alone. Differences in the C statistics were calculated overall and after stratifying participants into those not taking and taking antihypertensive medication. The 95% CIs for the C statistics and the differences in C statistics were calculated using 1000 iteration bootstraps with each iteration including the same sample size as in the main analyses.
P values <0.05 were considered statistically significant. All data analyses were conducted using SAS, version 9.4 (SAS Institute, Cary, NC), or Stata/IC, version 12.1 (Stata, Inc, College Station, TX).
Results
Participant Characteristics
Participants with higher 10-year predicted ASCVD risk were older, more likely to be men, have less than high school education, be current smokers, have diabetes mellitus and reduced estimated glomerular filtration rate, and to be taking antihypertensive medication (Table 1) . Mean total and low-density lipoprotein cholesterol were higher and highdensity lipoprotein cholesterol was lower among participants with higher 10-year predicted ASCVD risk. Also, those with higher ASCVD risk had higher clinic, daytime, nighttime, and 24-hour SBP, higher clinic and nighttime DBP, and a higher prevalence of prehypertension (Table I in the Data Supplement). Participant characteristics and the clinic and ambulatory BP levels among participants not taking and taking antihypertensive medication, separately, are reported in Table  II in the Data Supplement.
ASCVD Risk Category and Masked Hypertension
The prevalence of any masked hypertension, masked daytime hypertension, masked nighttime hypertension, and masked 24-hour hypertension was 54.0%, 31.5%, 49.2%, and 34.8%, respectively. Participants with higher ASCVD risk had a higher prevalence of each type of masked hypertension ( Figure 1 ). As compared with 10-year predicted ASCVD risk <5%, the adjusted prevalence ratio (95% CI) for having any masked hypertension was 1.36 (1.03-1.79), 1.62 (1.22-2.16), and 1.91 (1.47-2.48) for 10-year predicted ASCVD risk ≥5% to <7.5%, ≥7.5% to <10%, and ≥10%, respectively (P-trend=<0.001; Table 2 ). Similar findings were observed for masked daytime hypertension, masked nighttime hypertension, and masked 24-hour hypertension, and among participants not taking and taking antihypertensive medication, separately (Table III in 
Prevalence of ASCVD Risk Category by Masked Hypertension Status
The percentage of participants with 10-year predicted ASCVD risk ≥10% was higher among those with versus without any masked hypertension (50.9% versus 29.7%), masked daytime hypertension (54.7% versus 34.9%), masked nighttime Table IV in the Data Supplement). Among participants not taking and taking antihypertensive medication, separately, the percentage in the ≥7.5% ASCVD risk category was higher among those with versus without each type of masked hypertension (Table V in 
ASCVD Risk Category and Masked Hypertension, Stratified by Prehypertension Status
The prevalence of 10-year predicted ASCVD risk ≥10% was 25.6% and 50.0% for participants with normal clinic BP and prehypertension, respectively. Among participants with normal clinic BP, as compared with 10-year predicted ASCVD risk <5%, the adjusted prevalence ratio (95% CI) for having any masked hypertension was 1.73 (1.01-2.97), 1.88 (1.00-3.54), and 2.22 (1.24-3.99) for 10-year predicted ASCVD risk ≥5% to <7.5%, ≥7.5% to <10%, and ≥ 10%, respectively (P-trend=0.015; Table VI in the Data Supplement). Similar findings were observed for masked nighttime hypertension but not masked daytime hypertension or masked 24-hour hypertension. Among participants with prehypertension, the adjusted prevalence ratio (95% CI) for having any masked hypertension was 1.06 (0.77-1.44), 1.29 (0.94-1.75), Table 4 in the Data Supplement. Cardiovascular Disease Risk and Masked Hypertension and 1.42 (1.07-1.89) for 10-year predicted ASCVD risk ≥5% to <7.5%, ≥7.5% to <10%, and ≥10%, respectively (P-trend=0.007). Similar findings were observed for masked daytime hypertension and masked 24-hour hypertension but not masked nighttime hypertension.
ASCVD Risk Category and Clinic BP for Detecting Masked Hypertension
The prevalence ratios for any masked hypertension were larger for each SD higher clinic SBP (1.31; 95% CI, 1.21-1.41) compared with each SD higher ASCVD risk score (1.23; 95% CI, 1.14-1.33) or clinic DBP (1.13; 95% CI, 1.05-1.22; Table 3 ). Similar findings were observed for masked daytime hypertension, masked nighttime hypertension, and masked 24-hour hypertension. The multivariable-adjusted C statistic for masked 24-hour hypertension was higher for clinic SBP and DBP versus ASCVD risk score (difference=0.036; 95% CI, 0.002-0.073) and lower for clinic DBP alone versus ASCVD risk score (difference=−0.033; 95% CI, −0.070 to −0.001; Table 4 ). There was no statistically significant difference in the C statistics for masked 24-hour hypertension associated with clinic SBP alone versus ASCVD risk score. Also, there were no statistically significant differences in the C statistic for any masked hypertension, masked daytime hypertension, and masked nighttime hypertension for clinic SBP and DBP, clinic SBP alone, and clinic DBP alone versus ASCVD risk score. There was no statistically significant difference in the C statistic for clinic SBP alone versus clinic SBP and DBP in detecting any masked hypertension, masked daytime hypertension, masked nighttime hypertension, or masked 24-hour hypertension. The C statistics for any masked hypertension, masked daytime hypertension, masked night- Table VII in the Data Supplement. Among participants not taking antihypertensive medication, the C statistics for any masked hypertension and masked daytime hypertension were higher for clinic SBP and DBP versus ASCVD risk score (difference=0.085; 95% CI, 0.037-0.150 and 0.039; 95% CI, 0.000-0.030, respectively). The C statistic for any masked hypertension was also higher for clinic SBP alone versus ASCVD risk score (difference=0.085; 95% CI, 0.038-0.154). Among participants taking antihypertensive medication, the C statistics for masked daytime hypertension, masked nighttime hypertension, and masked 24-hour hypertension were higher for both clinic SBP and DBP (dif- 
Discussion
In this population-based sample of blacks, higher 10-year predicted ASCVD risk was associated with a higher prevalence of any masked hypertension, masked daytime hypertension, masked nighttime hypertension, and masked 24-hour hypertension. These associations were consistent for participants taking and not taking antihypertensive medication, and among those with prehypertension and normal clinic BP. Also, a majority of participants with each type of masked hypertension had a 10-year predicted ASCVD risk ≥10%. The C statistic for discriminating between participants with versus without masked hypertension was similar or lower for predicted ASCVD risk when compared with clinic SBP and clinic DBP.
Previous studies of European and Japanese cohorts have demonstrated a high prevalence of masked hypertension and a strong association between masked hypertension and ASCVD events.
1,2,4-6 Similar observations have been made in the JHS. 3 In the current study, among participants with clinic SBP/ DBP <140/90 mm Hg, there was a high prevalence of masked hypertension, ranging from 31.5% to 54.0% depending on the type of masked hypertension being evaluated. There may be a role for masked hypertension screening using ABPM among blacks given its high prevalence and strong association with ASCVD events in this population. The optimal approach for identifying whom to screen for masked hypertension using ABPM is unknown. Several recent position papers, scientific statements, and guidelines recommend that ABPM should be used to assess out-ofclinic BP. 17, [22] [23] [24] [25] However, recommendations on who to screen with ABPM to identify masked hypertension were not provided. One approach may be to perform ABPM among all individuals with clinic SBP/DBP <140/90 mm Hg. We previously estimated that 153 million US adults would have to be screened using this approach, 26 making it impractical. Another strategy is to perform ABPM in individuals who have risk factors for masked hypertension. Previous studies have shown that among individuals with clinic SBP/DBP <140/90 mm Hg, higher clinic BP, particularly in the prehypertension range, is a strong predictor of masked hypertension. 1, 6, 20, 27 In the current analysis, higher 10-year predicted ASCVD risk, estimated with the pooled cohort risk equations, was associated with a higher prevalence of masked hypertension. However, the C statistic for discriminating between participants with versus without masked hypertension was similar or lower using predicted ASCVD risk when compared with clinic SBP and clinic DBP. Despite the prior evidence that several ASCVD risk factors are associated with masked hypertension, 1, 2, 21, 28, 29 clinic BP, particularly in the prehypertension range, 1, 6, 20, 26 may be sufficient for identifying individuals with masked hypertension.
In the 2013 guidelines for the management of arterial hypertension, the European Society of Hypertension and European Society of Cardiology recommended that lifestyle measures and antihypertensive drug treatment should be considered for individuals with masked hypertension (class IIa recommendation, level C evidence). 30 However, there have been no randomized trials evaluating whether these interventions reduce the risk of ASCVD events among individuals with masked hypertension. There is increasing evidence that predicted ASCVD risk should be considered when deciding when to initiate or intensify hypertension treatment. 31, 32 In the current study, the majority (50.9%) of participants with any masked hypertension were in the highest (≥10%) ASCVD risk category. Individuals with masked hypertension and elevated ASCVD risk might derive a greater absolute cardiovascular benefit from treatment compared with individuals with masked hypertension and low ASCVD risk. 31 Therefore, using elevated ASCVD risk as a screening criterion for conducting ABPM may identify the majority of individuals with masked hypertension and the majority of those likely to have ASCVD events. 19 We acknowledge that a large percentage (38.2%) of participants with the lowest ASCVD risk (<5%) had any masked hypertension. It remains unknown whether masked hypertension is associated with an increased risk of ASCVD events among individuals with low predicted ASCVD risk. It is likely that antihypertensive medication treatment will have limited benefit in this group given their low predicted ASCVD risk. This issue has important implications for whether ABPM should be performed for individuals with low ASCVD risk to identify masked hypertension and underscores the need for further research in this area.
There are several strengths of the current study. We used data from JHS-a population-based cohort-comprised of blacks with a broad range of ASCVD risk. The JHS includes one of the largest samples of ABPM conducted among blacks, and ABPM and clinic BP were conducted following standardized protocols. The large sample size allowed us to evaluate the association between ASCVD risk categories and masked hypertension among participants with normal clinic BP and prehypertension, separately, and by antihypertensive medication use. There are also several potential limitations to the current study. Participants in the JHS underwent only 1 ABPM session, and, therefore, we cannot exclude the possibility that the results would have differed with the inclusion of additional 24-hour periods of ABPM. Without additional ABPM recordings before visit 1, it is also not possible to determine how long participants had masked hypertension. Further, clinic BP was measured using a manual device. However, for the current analysis, clinic BP values were calibrated with an oscillometric device. Finally, there was a relatively small sample size in some of the ASCVD risk categories in the subgroup analyses.
In conclusion, among blacks without BP in the hypertensive range based on clinic measurements, higher ASCVD risk was associated with a higher prevalence of any masked hypertension, masked daytime hypertension, masked nighttime hypertension, and masked 24-hour hypertension. Over 50% of participants with each type of masked hypertension had a 10-year predicted ASCVD risk ≥10%. The C statistic discriminating between individuals with and without masked hypertension associated with ASCVD risk was equivalent to or lower than clinic-measured BP. However, risk prediction equations may be useful for identifying individuals with both masked hypertension and increased ASCVD risk who may derive the greatest absolute risk reduction from antihypertensive treatment.
